Amgen resolves patent suit, squashing Teva's neutropenia biosimilar until 2013
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries and Amgen have resolved patent litigation in the US related to a Teva biosimilar (pending at the US FDA) that Amgen claimed infringes its patents covering Neupogen (filgrastim).